A detailed history of New York State Common Retirement Fund transactions in Nektar Therapeutics stock. As of the latest transaction made, New York State Common Retirement Fund holds 18,800 shares of NKTR stock, worth $20,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,800
Previous 87,800 78.59%
Holding current value
$20,116
Previous $109,000 77.98%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$1.11 - $1.48 $76,590 - $102,120
-69,000 Reduced 78.59%
18,800 $24,000
Q2 2024

Jul 31, 2024

BUY
$0.9 - $1.83 $79,020 - $160,674
87,800 New
87,800 $109,000
Q2 2023

Aug 07, 2023

SELL
$0.53 - $1.03 $42,456 - $82,510
-80,107 Reduced 98.41%
1,293 $1,000
Q1 2023

May 02, 2023

SELL
$0.64 - $3.15 $21,696 - $106,785
-33,900 Reduced 29.4%
81,400 $57,000
Q3 2022

Nov 08, 2022

BUY
$3.04 - $5.14 $40,298 - $68,135
13,256 Added 12.99%
115,300 $369,000
Q2 2022

Aug 04, 2022

SELL
$3.17 - $6.17 $310,520 - $604,388
-97,956 Reduced 48.98%
102,044 $388,000
Q1 2022

May 05, 2022

SELL
$4.16 - $13.72 $2,758 - $9,096
-663 Reduced 0.33%
200,000 $1.08 Million
Q4 2021

Feb 02, 2022

SELL
$10.83 - $18.41 $1,245 - $2,117
-115 Reduced 0.06%
200,663 $2.71 Million
Q3 2021

Nov 02, 2021

BUY
$13.07 - $18.84 $10,168 - $14,657
778 Added 0.39%
200,778 $3.61 Million
Q2 2021

Aug 02, 2021

BUY
$16.52 - $20.4 $102,424 - $126,479
6,200 Added 3.2%
200,000 $3.43 Million
Q1 2021

May 11, 2021

SELL
$16.56 - $25.46 $587,880 - $903,830
-35,500 Reduced 15.48%
193,800 $3.88 Million
Q4 2020

Feb 08, 2021

SELL
$15.77 - $19.03 $326,439 - $393,921
-20,700 Reduced 8.28%
229,300 $3.9 Million
Q3 2020

Nov 05, 2020

SELL
$16.59 - $24.79 $527,562 - $788,322
-31,800 Reduced 11.28%
250,000 $4.15 Million
Q2 2020

Aug 07, 2020

SELL
$16.86 - $23.44 $182,088 - $253,152
-10,800 Reduced 3.69%
281,800 $6.53 Million
Q4 2019

Feb 05, 2020

SELL
$15.87 - $23.12 $158,700 - $231,200
-10,000 Reduced 3.3%
292,600 $6.32 Million
Q3 2019

Nov 07, 2019

SELL
$16.91 - $36.27 $152,190 - $326,430
-9,000 Reduced 2.89%
302,600 $5.51 Million
Q2 2019

Aug 09, 2019

BUY
$31.0 - $36.3 $514,600 - $602,580
16,600 Added 5.63%
311,600 $11.1 Million
Q1 2019

May 08, 2019

SELL
$31.58 - $46.35 $154,742 - $227,115
-4,900 Reduced 1.63%
295,000 $9.91 Million
Q4 2018

Feb 08, 2019

SELL
$30.43 - $56.65 $410,805 - $764,775
-13,500 Reduced 4.31%
299,900 $9.86 Million
Q3 2018

Nov 07, 2018

BUY
$46.46 - $68.49 $66,902 - $98,625
1,440 Added 0.46%
313,400 $19.1 Million
Q2 2018

Aug 10, 2018

BUY
$46.25 - $104.45 $6.6 Million - $14.9 Million
142,750 Added 84.36%
311,960 $15.2 Million
Q1 2018

May 10, 2018

SELL
$57.4 - $108.44 $33,005 - $62,353
-575 Reduced 0.34%
169,210 $18 Million
Q4 2017

Feb 13, 2018

SELL
$23.02 - $60.5 $908,921 - $2.39 Million
-39,484 Reduced 18.87%
169,785 $10.1 Million
Q3 2017

Nov 06, 2017

SELL
$17.79 - $24.0 $1.21 Million - $1.63 Million
-67,915 Reduced 24.5%
209,269 $5.02 Million
Q2 2017

Aug 11, 2017

BUY
N/A
277,184
277,184 $5.42 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.